Charcot‑Marie‑Tooth disease type 1E (CMT1E) is a genetic neuropathy that weakens the nerves in the arms and legs. People with CMT1E often notice foot weakness, ankle sprains, tripping, and numbness or tingling, and doctors may see high arches and reduced reflexes. Early symptoms of Charcot‑Marie‑Tooth disease type 1E usually begin in childhood or adolescence and tend to progress slowly over life. Most people with CMT1E have a normal life span, but daily activities can be affected. Treatment focuses on support like physical therapy, ankle‑foot orthoses, pain control, and regular check‑ins with neurology and rehabilitation teams.
Overview
Charcot-marie-tooth disease type 1eSymptoms
Charcot-Marie-Tooth disease type 1E often causes slowly worsening weakness and wasting in the feet and lower legs, leading to tripping, ankle sprains, and high-arched feet. Numbness, tingling, and balance troubles are common. Hand weakness may appear later.
Outlook and prognosis
Many living with Charcot-Marie-Tooth disease type 1E notice slowly progressive weakness and numbness in the feet and hands, often starting in childhood or adolescence. Most people remain mobile and independent for many years with tailored therapy and supportive devices. Outlook varies by family and gene change, so regular follow-up helps adjust care early.
Causes and risk factors
Charcot-Marie-Tooth disease type 1E is caused by mutations in a myelin gene, most often PMP22. It’s usually inherited in an autosomal-dominant pattern, though new mutations occur. Family history raises risk; diabetes, alcohol misuse, and neurotoxic drugs can worsen nerve problems.
Genetic influences
Genetics are central in Charcot-Marie-Tooth disease type 1E; inherited variants in PMP22 typically cause it. Most cases are autosomal dominant, though new (de novo) variants occur. Variant type can influence age at onset, progression, and severity.
Diagnosis
Doctors suspect Charcot-Marie-Tooth disease type 1E from clinical features and family history, supported by nerve conduction studies showing demyelination. The genetic diagnosis of Charcot-Marie-Tooth disease type 1E is confirmed by genetic tests, usually PMP22 sequencing; nerve biopsy is rarely needed.
Treatment and drugs
Treatment for Charcot‑Marie‑Tooth disease type 1E focuses on keeping you mobile, comfortable, and independent. Care often includes physical and occupational therapy, custom braces or splints, pain control, and foot care, with surgery for severe deformities. Regular check-ins, fall‑prevention, and genetic counseling support long‑term planning.
Symptoms
Daily life may include ankles that tire quickly, more trips on flat ground, or buttons taking more effort. Early features of Charcot-Marie-Tooth disease type 1E often show up in the feet and lower legs, with weakness, changes in foot shape, and reduced feeling. Features vary from person to person and can change over time. Some people notice only mild changes, while others have issues with balance, cramps, or nerve pain.
Muscles in the feet and ankles feel weak, making it hard to stand on toes or heels. This can make stairs, hills, or long walks tougher.
Toes catch the ground because the ankle doesn’t lift well. This is common in Charcot-Marie-Tooth disease type 1E and may lead to a higher-stepping walk to avoid tripping.
Feet often develop high arches with curled toes. This foot shape is typical in Charcot-Marie-Tooth disease type 1E and can cause shoe-fit problems, pressure points, and calluses.
Grip strength may fade and tasks like opening jars or turning keys get harder. Hands can also be affected in Charcot-Marie-Tooth disease type 1E.
How people usually first notice Charcot-marie-tooth disease type 1e?
Many families first notice Charcot-Marie-Tooth disease type 1E when a child seems clumsier than peers, trips often, or develops a slapping or high-stepping walk; parents or doctors may also see foot changes like high arches or hammertoes and weaker ankles. As school years begin, fine motor tasks can feel harder, with hand weakness, trouble buttoning clothes, or reduced grip strength, and a pediatric exam may find decreased reflexes and reduced vibration or touch sensation in the feet. These “first signs of Charcot-Marie-Tooth disease type 1E” often lead to nerve conduction testing and genetic evaluation to confirm the diagnosis.
Types of Charcot-marie-tooth disease type 1e
Charcot-Marie-Tooth disease type 1E (CMT1E) is a genetic neuropathy, meaning it affects the peripheral nerves that control movement and feeling in the limbs. Within CMT, there are several clinical variants based on the gene involved; CMT1E refers to changes in the PMP22 gene that cause a demyelinating form. People may notice different sets of symptoms depending on their situation. When reading about types of Charcot-Marie-Tooth, you’ll often see them grouped by gene and by whether the nerve’s insulating “myelin” or the nerve fiber itself is mainly affected.
Classic CMT1E
Early-onset weakness in the feet and ankles with frequent tripping and high arches is common. Nerve tests typically show slow signal speeds consistent with demyelination. Hand weakness and numbness often appear later.
Infantile-onset CMT1E
Symptoms begin in the first years of life with delayed walking, “floppy” tone, and marked foot deformities. Weakness and sensory loss can be more pronounced than in classic cases. Breathing or swallowing issues are uncommon but can occur in more severe presentations.
Hearing-involved CMT1E
Alongside leg and hand weakness, people may develop gradual hearing difficulties. This reflects nerve involvement beyond the limbs in some variants of CMT1E. Hearing aids or other supports can help communication and daily life.
Cranial-nerve–predominant CMT1E
Facial weakness or swallowing challenges accompany limb symptoms in this less common pattern. Doctors sometimes classify symptoms as motor versus sensory. Care plans often include speech and swallowing therapy if needed.
Severe early CMT1E
A rarer, rapidly progressive course can cause significant disability in childhood. Even within the same type, intensity can range from mild to severe. Early multidisciplinary care can support mobility and comfort.
What genetics can tell you about symptoms
Some people with Charcot–Marie–Tooth disease type 1E (CMT1E) have specific PMP22 gene changes that cause earlier nerve damage, leading to foot weakness, high arches, numbness, and balance problems. Certain variants can bring symptoms in childhood and progress faster than typical CMT1.
Causes and risk factors
In Charcot-Marie-Tooth disease type 1E, the main cause is a change in the PMP22 gene. This change is usually inherited in an autosomal dominant pattern, but it can also appear for the first time. Doctors distinguish between risk factors you can change and those you can’t. Family history is the key non-modifiable risk, and disease severity can differ even within the same family. Nerve-toxic medicines, heavy alcohol use, and health problems like diabetes can worsen nerve problems in Charcot-Marie-Tooth disease type 1E.
Environmental and biological risk factors
Understanding what can raise the chance of Charcot-Marie-Tooth disease type 1E can help when planning a pregnancy or reviewing past exposures. Doctors often group risks into internal (biological) and external (environmental). Below are environmental and biological risk factors for Charcot-Marie-Tooth disease type 1E that may influence how often new cases arise. These factors do not guarantee the condition; at most, they shift the odds slightly.
Older fathers have a higher chance of new DNA changes arising in sperm. This slightly increases the likelihood that a child could be born with Charcot-Marie-Tooth disease type 1E. The effect grows gradually with age rather than at one specific cutoff.
Older egg cells carry a modestly higher rate of new DNA changes. This may slightly raise the chance of a new case occurring. The increase is generally smaller than the paternal-age effect.
Exposure to high levels of radiation before conception, such as some cancer treatments or industrial accidents, can damage reproductive cells. This can modestly raise the chance of new harmful DNA changes in an egg or sperm. Routine medical imaging uses much lower doses and is not known to raise this risk.
Certain cancer medicines given before conception can harm DNA while eggs or sperm are developing. This may slightly increase the chance of a child with Charcot-Marie-Tooth disease type 1E. Timing pregnancy after treatment can reduce residual risk.
Genetic risk factors
Charcot-Marie-Tooth disease type 1E (CMT1E) arises from harmful changes in a single gene called PMP22. These genetic changes disrupt how the myelin sheath forms around peripheral nerves, which interferes with nerve signaling. In many families, CMT1E follows an autosomal dominant pattern and can pass from one generation to the next. Risk is not destiny—it varies widely between individuals.
PMP22 changes: Pathogenic changes in the PMP22 gene are the direct cause of CMT1E. They can alter the amount or shape of the PMP22 protein, which disrupts myelin around peripheral nerves. These changes differ from the common PMP22 duplication seen in CMT1A.
Dominant inheritance: One altered copy of PMP22 is enough to cause the condition. Each child of an affected parent has a 50% (1 in 2) chance to inherit the variant.
De novo variants: Some people develop CMT1E because of a new PMP22 change that arose in the egg or sperm. This explains first-in-the-family cases with no prior history. Testing parents helps estimate recurrence risk.
Variable expressivity: The same PMP22 variant can lead to different ages of onset and severity, even within one family. Some remain mildly affected for years, while others notice difficulties in childhood. This variability influences prognosis and planning.
Reduced penetrance: A few PMP22 variants show incomplete penetrance, so not everyone who carries the change develops clear signs. This can make family histories look skipped across generations. An apparently unaffected parent can still pass on the variant.
Early-onset variants: Certain PMP22 changes are linked to earlier and more severe nerve damage. When present, early symptoms of Charcot-Marie-Tooth disease type 1E may appear in childhood. Other variants are associated with later onset.
Lifestyle risk factors
Lifestyle habits do not cause Charcot-marie-tooth disease type 1e (CMT1E), but they can meaningfully influence symptoms, daily function, and complication risk. Understanding how lifestyle affects Charcot-marie-tooth disease type 1e can help you prioritize what matters most. Small, consistent choices around movement, foot care, sleep, and substance use can reduce falls, pain, and deconditioning.
Regular low-impact exercise helps maintain muscle strength and balance in CMT1E. Overexertion or high-impact workouts can increase fatigue, sprains, and falls.
Daily calf, hamstring, and hand stretching can reduce contractures and cramps in CMT1E. Skipping stretching may worsen stiffness and gait mechanics.
Excess body weight increases stress on weak ankles and knees, worsening pain and mobility in CMT1E. Modest weight loss can improve endurance and brace comfort.
Heavy or frequent drinking can aggravate neuropathy, tremor, and balance problems in CMT1E. Limiting alcohol may reduce numbness flares and fall risk.
Risk prevention
Charcot-Marie-Tooth disease type 1E (CMT1E) is inherited, so you can’t stop the condition itself from developing, but you can lower the chance of complications and reduce day-to-day impact. Practical steps focus on protecting nerves and muscles, preventing falls and foot wounds, and keeping joints flexible and stable. Prevention works best when combined with regular check-ups.
Low‑impact exercise (like swimming or cycling) helps keep muscles strong and joints mobile. Balance and ankle‑stability work can lower fall and sprain risk in CMT1E.
Check skin, toes, and soles every day and keep nails tidy to spot hot spots, blisters, or cuts early. Well‑fitting shoes and breathable socks help prevent ulcers and infections in CMT1E.
Ankle‑foot orthoses and supportive shoes can improve walking and reduce ankle rolls. Early bracing in CMT1E may prevent falls and limit joint strain.
Clear cords and clutter, improve lighting, and use grab bars on stairs and in bathrooms. These changes lower fracture risk if balance or foot drop from CMT1E makes tripping more likely.
Transmission
Charcot‑Marie‑Tooth disease type 1E is a genetic condition, not an infection, so it cannot be caught or spread through touch, coughing, sex, food, or blood. It most often follows an autosomal dominant pattern—meaning if a parent lives with the condition, each child has a 50% chance of inheriting it. Genetic transmission of Charcot‑Marie‑Tooth disease type 1E can also occur as a new, spontaneous gene change in a child, even when neither parent has signs of the disease. Genetic counseling can help families understand how this condition is inherited, options for testing, and risks for future pregnancies.
When to test your genes
Consider genetic testing if you have progressive distal weakness, foot deformities, or sensory loss—especially with a family history of Charcot‑Marie‑Tooth disease. Test earlier if symptoms start in childhood, you’re planning a pregnancy, or results could guide braces, therapy, or monitoring for complications. Ask a genetics professional about targeted PMP22 testing and broader panels.
Diagnosis
Charcot-Marie-Tooth disease type 1E is typically identified by a pattern of nerve-related symptoms and confirmed with specific tests. Doctors look for signs like slowly worsening weakness in the lower legs and feet, balance changes, and foot shape differences, then use nerve studies and genetic testing to clarify the subtype. The diagnosis of Charcot-Marie-Tooth disease type 1E often combines what’s seen during the exam with test results. Some diagnoses are clear after a single visit, while others take more time.
Providers ask about when symptoms began, how they’ve changed, and any challenges with walking or hand tasks. Details like frequent ankle sprains, tripping, or high arches can be key clues. This helps decide which tests to order first.
The exam checks strength, reflexes, sensation, and gait. Findings often include weak ankle lifting, reduced reflexes, and decreased vibration sense in a pattern that fits a peripheral nerve problem. These features guide next steps.
A detailed family and health history can help identify inherited patterns across generations. Because CMT1E is usually autosomal dominant, multiple relatives may have similar symptoms, though severity can vary. Absence of family history does not rule it out due to possible new variants.
These tests measure how fast signals travel along the nerves. In CMT1E, speeds are typically slower, consistent with a demyelinating neuropathy, which helps separate it from axonal types. Results support the need for genetic confirmation.
Stages of Charcot-marie-tooth disease type 1e
Charcot-marie-tooth disease type 1e does not have defined progression stages. It tends to change slowly over many years, and the pattern and severity vary widely, so a standard staging system isn’t used. Different tests may be suggested to help confirm CMT1E, such as a neurological exam, nerve conduction studies (to see how fast signals travel), and genetic testing. Doctors also monitor strength, balance, and walking over time and may ask about early symptoms of Charcot-marie-tooth disease type 1e, such as frequent tripping or ankle weakness.
Outlook and prognosis
Living with Charcot-Marie-Tooth disease type 1E (CMT1E) often means gradual changes in strength and sensation, especially in the feet and lower legs, with hand involvement over time. Many people ask, “What does this mean for my future?”, and the short answer is that most people with CMT1E have a slow progression over many years, remaining active with adaptations like ankle supports, physical therapy, and pacing their day. Early symptoms of CMT1E can include frequent ankle sprains, tripping on uneven ground, or hand fatigue with buttons or keys, and these usually progress slowly rather than suddenly. Even though it can feel overwhelming, most people do not lose life expectancy from CMT1E itself.
The outlook is not the same for everyone, but many develop visible foot changes (high arches or hammertoes) and need orthotics or bracing to steady their gait. Weakness and numbness can increase in mid‑ to later adulthood, making longer walks or fine motor tasks harder, though plateaus are common and rapid declines are unusual. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Severe breathing or swallowing problems are uncommon in CMT1E; when they occur, they’re usually mild and manageable with targeted therapies.
Prognosis refers to how a condition tends to change or stabilize over time. With ongoing care, many people maintain independence at home, work, and school, using tailored exercise, good foot care, and pain strategies to preserve function. Serious complications like chronic foot ulcers or falls are the key drivers of disability, so preventing injuries and keeping joints flexible can meaningfully improve the long-term picture. Talk with your doctor about what your personal outlook might look like, including how your specific gene change, age at symptom onset, and current nerve function testing may shape your future.
Long-term effects
Living with Charcot-Marie-Tooth disease type 1E can change how hands and feet work in everyday life, from lacing shoes to keeping balance on uneven ground. Long-term effects vary widely, and not everyone follows the same path or pace. For some, changes unfold slowly over decades; for others, weakness or numbness shows up earlier in childhood and progresses more quickly. Doctors often describe these as long-term effects or chronic outcomes, shaped by how the nerves to the lower legs and hands are affected over time.
Weakness often starts in the feet and lower legs, then can involve the hands. Grip strength and ankle control may drop gradually. This can make stairs and fine finger tasks harder over time.
High arches or curled toes can develop as certain muscles weaken and tighten. These changes may become more pronounced with age. They can alter gait and shoe fit.
Unsteady footing and frequent tripping are common as ankle muscles weaken and sensation declines. Falls may become more likely on uneven ground or in the dark. Many notice slower walking to stay steady.
Numbness or reduced feeling in the feet and hands can progress. This can make it harder to sense temperature, pain, or where the feet are in space. Small injuries may go unnoticed.
How is it to live with Charcot-marie-tooth disease type 1e?
Living with Charcot–Marie–Tooth disease type 1E often means planning your day around energy and balance, because muscles in the feet, lower legs, and sometimes hands can feel weak and tire easily. Many rely on ankle–foot orthoses, supportive shoes, or hand grips to stay mobile and independent, and adapt tasks like writing, buttoning, or climbing stairs by pacing and using tools that protect joints and prevent falls. For family and friends, the biggest shifts are practical and emotional—offering a steady arm on uneven ground, allowing extra time, and understanding that fatigue and pain can flare after ordinary activities. With consistent routines, physical therapy, and small home adjustments, many build a reliable rhythm that keeps school, work, and social life moving forward.
Treatment and drugs
Treatment for Charcot-Marie-Tooth disease type 1E focuses on easing symptoms, protecting function, and maintaining independence over time. Supportive care can make a real difference in how you feel day to day, including regular physical therapy to keep muscles flexible and strong, occupational therapy to adapt daily tasks, and custom braces or orthotics to improve walking and reduce falls. Doctors sometimes recommend a combination of lifestyle changes and drugs, such as pain relievers for nerve pain or cramps, and treatment for related issues like sleep problems or mood changes. Surgery may be considered for foot deformities that cause pain or repeated injuries, especially if braces no longer provide enough support. Not every treatment works the same way for every person, so plan on periodic check-ins to fine-tune therapies and equipment as needs change.
Non-drug treatment
Non-drug care for Charcot–Marie–Tooth disease type 1E focuses on keeping you mobile, steady, and comfortable in daily life. Non-drug treatments often lay the foundation for long-term function, even if medicines or surgery are used later. Many start these supports when early symptoms of Charcot–Marie–Tooth disease type 1E appear, like ankle weakness, tripping, or hand fatigue.
Targeted exercises build strength where nerves still signal well. Gentle stretching helps keep joints flexible and reduces cramps. A therapist tailors a plan to your goals and safety needs.
Skills training makes dressing, writing, and kitchen tasks easier. Tools like easy-grip handles or button aids can reduce hand strain. This helps many with Charcot–Marie–Tooth disease type 1E stay independent at home and work.
Light braces support weak ankles so the toes clear the ground. They can improve balance and reduce falls. Your clinician adjusts the fit as Charcot–Marie–Tooth disease type 1E changes over time.
Supportive shoes and custom insoles spread pressure and improve alignment. This can ease foot pain and reduce corns or calluses. A podiatrist can guide choices for Charcot–Marie–Tooth disease type 1E.
Your genes may have an impact on how drugs work for you
Medicines used in Charcot–Marie–Tooth disease type 1E can act differently depending on your genes, which influence how fast drugs are absorbed, broken down, or cleared. Genetic variants in nerve-structure genes and liver enzymes may change benefits, side effects, or best dosing.
Pharmacological treatments
For Charcot-Marie-Tooth disease type 1E, medicines aim to ease symptoms like nerve pain and muscle cramps; there’s no approved drug that changes the course of the condition yet. Neuropathic pain is common and, for some, can even be among the early symptoms of Charcot-Marie-Tooth disease type 1E. Not everyone responds to the same medication in the same way. Your clinician will tailor options to your goals, other health conditions, and side effect preferences.
Often used for nerve pain in CMT1E. Dosing may be increased or lowered gradually to find the lowest dose that helps. Sleepiness and dizziness are the most common side effects.
Similar to gabapentin but may work faster for some. It can cause swelling in the legs, weight gain, or sleepiness. Dose adjustments are needed with kidney issues.
Helps neuropathic pain and can also support mood or anxiety if present. Nausea or dry mouth may occur early on and often improve. Avoid if you have severe liver disease or heavy alcohol use.
A bedtime option that eases nerve pain and can improve sleep. Dry mouth, constipation, and daytime grogginess can happen. It may not suit people with certain heart rhythm problems.
Genetic influences
In Charcot-Marie-Tooth disease type 1E, a single altered copy of the PMP22 gene, which helps build the nerve’s protective covering, is typically enough to cause the condition. This follows an autosomal dominant pattern, so each child of an affected parent has a 50% chance of inheriting the gene change, though some people are the first in their family because it arose new (de novo). The same PMP22 change can lead to very different levels of weakness, numbness, or walking difficulty among relatives, and early symptoms of Charcot-Marie-Tooth disease type 1E may show up in childhood or not until later. Genetic testing can confirm the specific change in PMP22 and helps tell CMT1E apart from other Charcot-Marie-Tooth types. To put these pieces together, doctors may suggest genetic counseling. Understanding the inheritance of CMT1E can guide monitoring, treatment planning, and family planning decisions.
Is Charcot-marie-tooth disease type 1e genetic?
Genetics are central in Charcot-Marie-Tooth disease type 1E; inherited variants in PMP22 typically cause it. Most cases are autosomal dominant, though new (de novo) variants occur. Variant type can influence age at onset, progression, and severity.
Pharmacogenetics—how genetics influence drug effects
Treatment choices often consider genetics, both the gene causing the neuropathy and separate genes that affect how your body handles medicines. In Charcot-Marie-Tooth disease type 1E, changes in the PMP22 gene make peripheral nerves more fragile, so doctors avoid drugs known to injure nerves—especially the chemotherapy medicine vincristine, which can cause severe, sometimes lasting worsening. Genetic testing can sometimes identify how your body breaks down certain pain medicines and antidepressants used for nerve pain, helping tailor the dose or choose a safer option. For example, differences in liver enzyme genes may make codeine or tramadol either ineffective or too strong, and can influence older antidepressants like amitriptyline or nortriptyline that are often used for nerve pain. These results don’t diagnose or change the course of CMT1E itself, but they can reduce trial-and-error and side effects when managing pain, sleep, or mood. Your care team will weigh genetic results alongside your age, other conditions, and non-drug therapies such as braces and physical therapy, and will flag any medicines that could worsen your neuropathy.
Interactions with other conditions
People with Charcot-marie-tooth disease type 1e (CMT1E) who also live with diabetes often notice more numbness, burning pain, or balance trouble, and sores on the feet can take longer to heal. Day-to-day, it can feel like one health issue amplifies the other. Thyroid problems, kidney disease, low vitamin B12, and heavy alcohol use can further aggravate nerve damage, making early symptoms of Charcot-marie-tooth disease type 1e harder to spot. Some medicines that affect nerves—most notably certain chemotherapy drugs like vincristine—can cause sudden, severe worsening, so it’s important to make sure every clinician knows about your underlying neuropathy before starting new treatments. If weakness worsens quickly or becomes very uneven from one side to the other, an added inflammatory nerve condition may be present; this overlap can sometimes be treated differently than CMT1E alone. Foot and ankle arthritis or joint instability can compound the high-arched feet and muscle weakness seen in CMT1E, raising fall risk and making bracing or physical therapy even more important.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns that certain relatives walked a bit differently, wore out the sides of their shoes, or tripped more often on uneven ground. Long before scans and genetic tests, people with what we now call Charcot‑Marie‑Tooth disease type 1E often recalled childhood ankle weakness, high arches, and trouble keeping up in sports. Some were given shoe inserts; others learned to avoid long walks. Features varied from one generation to the next, which made the condition hard to pin down.
First described in the medical literature as part of the broader Charcot‑Marie‑Tooth (CMT) group in the late 1800s, these nerve problems were initially sorted by what doctors saw and felt during exams—muscle wasting in the calves and feet, reduced reflexes, and changes in sensation. Over time, descriptions became more specific as researchers noticed that some families had additional features, like early hearing loss or differences seen on nerve tests, suggesting more than one pathway to similar symptoms.
As medical science evolved, nerve conduction studies in the mid‑20th century helped split CMT into types that affect the insulating sheath of nerves (demyelinating) and those that affect the nerve fiber itself (axonal). CMT1E falls within the demyelinating group. It was recognized as a distinct subtype when researchers linked certain families to changes in a single gene on chromosome 19, now known as PMP22. Unlike the more common CMT1A, which usually involves an extra copy of this gene, CMT1E is typically caused by a point change in the gene’s code that disrupts how the nerve’s insulation is made.
In recent decades, knowledge has built on a long tradition of observation. Advances in genetics confirmed that different alterations in the same gene can lead to different forms of CMT, which explained why two relatives might share high arches but differ in age of onset or severity. This also clarified why some people with CMT1E developed symptoms in early childhood, while others noticed changes later, and why hearing or balance issues appeared in some families but not others.
Genetic testing in the 1990s and 2000s made it possible to identify PMP22 variants directly, moving diagnosis from educated guesswork to confirmation. For many, this reduced years of uncertainty, guided choices about physical therapy and bracing, and informed family planning. Today, the history of Charcot‑Marie‑Tooth disease type 1E reflects a broader shift in neurology: from grouping conditions by how they look and feel to understanding them by their underlying biology, with the hope that targeted treatments will follow.